2/12/2013




PHARMACOLOGY
INTRO DEFINATION

  Zulcaif Ahmad


                              1
2/12/2013




TOPIC
1)   Bioavailability
2)   Bioequivalence
3)   Therapeutic index
4)   Plasma half life
5)   Dose response curve
6)   Area under curve (AUC)
7)   Volume of distribution

                                          2
2/12/2013




PHARMACOKINETICS

    Pharmakon ( drug )
    Kinetics ( motion )
 Definition : The actions of the body on an
  administered drug ( dose concentration ).
          It involves drug absorption ,
  distribution , metabolism and elimination .



                                                3
2/12/2013




PHARMACOKINETICS




                               4
2/12/2013




                        Pharmacokinetics
                           conc. vs time
Conc.(mg/L)




              0.0

                    0                                  25


                            Time (h)


                                                            5
2/12/2013




1) BIOAVAILABILITY
   In pharmacology, bioavailability is a measurement of the rate and extent to
    which a drug reaches the systemic circulation It is denoted by the letter f

   Bioavailability is the ratio of the area calculated for oral route of
    administration to the intravenous route of administration.

   In pharmacology, bioavailability (BA) is a subcategory of absorption and is
    the fraction of an administered dose of unchanged drug that reaches
    the systemic circulation, one of the principal pharmacokinetic properties
    of drugs. By definition, when a medication is administered intravenously, its
    bioavailability is 100%.

   However, when a medication is administered via other routes (such as
    orally), its bioavailability generally decreases (due to incomplete absorption
    and first-pass metabolism) or may vary from patient to patient.

   Bioavailability is one of the essential tools in pharmacokinetics, as
    bioavailability must be considered when calculating dosages for non-
    intravenous routes of administration.


                                                                                     6
2/12/2013




For a non-intravenous drug , it is less than
 100% because of :
        1) Absorption Parameters.
        2)First-pass elimination.
 Bioavailability is the drug proportion that
 actually reaches systemic circulation .



                                                7
2/12/2013




            8
2/12/2013




2) BIOEQUIVALENCE
 Relationship between 2 preparations of the
  same drug at same dose in same form with
  similar bioavailability.
                 OR
 The relationship between two preparations of
  the same drug in the same dosage form that
  have a similar bioavailability.


                                             9
2/12/2013




   Bioequivalence is a term in pharmacokinetics used to assess the
    expected in vivo biological equivalence of two proprietary
    preparations of a drug. If two products are said to be bioequivalent it
    means that they would be expected to be, for all intents and
    purposes, the same.

   two pharmaceutical products are bioequivalent if they are
    pharmaceutically equivalent and their bioavailabilities (rate and
    extent of availability) after administration in the same molar dose are
    similar to such a degree that their effects, with respect to both
    efficacy and safety, can be expected to be essentially the same.

   Pharmaceutical equivalence implies the same amount of the same
    active substance(s), in the same dosage form, for the same route of
    administration and meeting the same or comparable standards."[1]


                                                                          10
2/12/2013




GRAPH SHOWING BIOEQUIVALENCE

                         90
                         80
                   mL)




                         70
 Concentration (ng/




                         60
                                                                         Test/Generic
                         50
                                                                         Reference/Brand
                         40
                         30
                         20
                         10
                         0
                              0   5   10       15         20   25   30
                                           Time (hours)

                                                                                           11
2/12/2013




3) THERAPEUTIC INDEX
 The difference between the minimum
  therapeutic and minimum toxic
  concentrations of a drug.
 Therapeutic index represents the safety of
  a drug.
 Drugs having low therapeutic index include:


    Anticonvulsants, lithium,     anticoagulants,
    corticosteroids and cardio active drugs.

                                                12
2/12/2013




   therapeutic index (also known as therapeutic ratio)
    is a comparison of the amount of a therapeutic agent
    that causes the therapeutic effect to the amount that
    causes death (in animal studies) or toxicity (in human
    studies).
   the ratio between the dosage of a drug that causes a
    lethal effect and the dosage that causes therapeutic
    effect.
   Medical Dictionary :
     The ratio between the toxic dose and the therapeutic
    dose of a drug, used as a measure of the relative
    safety of the drug for a particular treatment.

                                                         13
2/12/2013




4) PLASMA HALF LIFE
   The duration of action of a drug is known as its half life.

   This is the period of time required for the concentration or amount of
    drug in the body to be reduced by one-half.

   Drug can be eliminated from the body, or it can be translocated to
    another body fluid compartment such as the intracellular fluid or it can
    be destroyed in the blood after it is reduced to half life.

    The removal of a drug from the plasma is known as clearance and the
    distribution of the drug in the various body tissues is known as
    the volume of distribution. Both of these pharmacokinetic parameters
    are important in determining the half life of a drug.

   Here is the symbol to represent the half-life: t½


                                                                               14
2/12/2013




 The biological half-life or elimination half-
  life of a substance is the time it takes for a
  substance (for example
  a metabolite, drug, signaling molecule,
  radioactive nuclide, or other substance) to lose
  half of its pharmacologic, physiologic, or
  radiologic activity , as per the MeSH definition.
 Biological half-life is an
  important pharmacokinetic parameter .

                                                      15
2/12/2013




            16
2/12/2013




5) DOSE-RESPONSE CURVE
   A dose–response curve is a simple X–Y graph relating the magnitude of a stressor ( e.g.
    amount of drug ) to the response of receptor.

   The measured dose (usually in milligrams, micrograms, or grams per kilogram of body-
    weight for oral exposures or milligrams per cubic meter of ambient air for inhalation
    exposures) is generally plotted on the X axis and the response is plotted on the Y axis.

   The dose–response relationship , describes the change in effect on an organism caused
    by differing levels of exposure (or doses) to a stressor (usually a chemical) after a certain
    exposure time.[1] This may apply to individuals (e.g.: a small amount has no significant
    effect, a large amount is fatal), or to populations (e.g.: how many people or organisms are
    affected at different levels of exposure).

   Studying dose response, and developing dose response models, is central to determining
    "safe" and "hazardous" levels and dosages for drugs, potential pollutants, and other
    substances to which humans or other organisms are exposed. These conclusions are often
    the basis for public policy.

   Dose–response relationships generally depend on the exposure time and exposure route
    (e.g., inhalation, dietary intake); quantifying the response after a different exposure time or
    for a different route leads to a different relationship and possibly different conclusions on
    the effects of the stressor under consideration.




                                                                                                      17
2/12/2013




6) AREA     UNDER CURVE (AUC)
 The area under the plot of plasma concentration
  of drug (not logarithm of the concentration)
  against time after drug administration
 The area under the plasma (serum, or blood)
  concentration versus time curve (AUC) has a
  number of important uses in pharmacokinetics.
 The AUC is of particular use in estimating
  bioavailability of drugs, and in estimating total
  clearance of drugs (ClT).

                                                  18
2/12/2013




            19
2/12/2013




   AUC can be used as a measure of drug exposure. It is
    derived from drug concentration and time so it gives a
    measure how much - how long a drug stays in a body.

   The AUC measured after administration of a drug product
    is an important parameter in the comparison of drug
    products. These bioequivalence or bioavailability
    studies can be analyzed by comparing AUC values.

   Drug AUC values can be used to determine other
    pharmacokinetic parameters, such as clearance or
    bioavailability, F. Similar techniques can be used to
    calculate area under the first moment curve (AUMC)

                                                             20
2/12/2013




7) VOLUME                 OF DISTRIBUTION
   Volume of distribution is the measure of the apparent space in the
    body available to contain the drug.

   Volume of distribution relates the amount of drug in the body to the
    concentration of drug in blood or plasma .

   Formula for volume of distribution is , total amount of drug in the
    body divided by drug blood plasma concentration.

   It is not a real but a theoretical volume.

   if VD is greater, it shows that the drug is more diluted than it should
    be (in the blood plasma), meaning more of it is distributed in tissue
    (i.e. not in plasma).

    It is defined as the distribution of a medication between plasma and
    the rest of the body after oral or parenteral dosing.
                                                                              21
2/12/2013




   Volume of distribution may be increased
    by renal failure (due to fluid retention)
    and liver failure (due to altered body fluid).

   Conversely it may be decreased in
    dehydration.




                                                     22
2/12/2013




            23
2/12/2013




REFERENCE
 http://bipolar.about.com/od/medications/g/gl_bio
  availabil.htm
 http://faculty.ksu.edu.sa/hisham/Documents/Stu
  dents/a_PHCL/pkin08.pdf
 http://www.wisegeek.com/what-is-
  bioequivalence.htm#did-you-know
 Stedman's medical dictionary .
 Medical-dictionary.thefreemedicaldictionary.com
 www.freedictionry.com


                                                 24
2/12/2013




THANK YOU…




                         25
2/12/2013




ANY QUESTION ???



                               26

More Related Content

PDF
Pharmacokinetics / Biopharmaceutics - Multi dosage regimens
PPTX
Pharmacokinetic parameters
PPTX
Phytosome
PPTX
immunostimulants
PPTX
PPTX
Rheumatoid arthritis
PPTX
Pharmacokinetics of multiple dosing
Pharmacokinetics / Biopharmaceutics - Multi dosage regimens
Pharmacokinetic parameters
Phytosome
immunostimulants
Rheumatoid arthritis
Pharmacokinetics of multiple dosing

What's hot (20)

PPTX
Oral contraceptives
PDF
Experiment Findings Formulation and Evaluation of PCM Tablet.pdf
PDF
Factors affecting absorption of drugs
PPTX
Nootropics (M.Pharm)
PPTX
Soaps and syndetbars
PPTX
Evaluation of antidepressants.pptx
PDF
Bio assay of d-tubocurarine
PPTX
extravascular urin.pptx
PPT
A seminar on one & two compartment open model extra vascular administration
PDF
Expt 5 three point bioassay
PPTX
IN-VITRO-IN VIVO CORRELATION (IVIVC).pptx
PPTX
Screening of antidepressant
PPT
Microspheres - Methods for Preparation of Microspheres
PPTX
Liposomes - Targeted drug delivery system
PPTX
Bioavailability and bioequivalence
PPTX
Absolute bioavailability & relative bioavailability
PPT
Controlled Release Oral Drug Delivery System
PDF
Methods for Measurement of bioavailability
PPTX
EVOLUTION OF COSMECEUTICAL FROM COSMETIC
PDF
Analeptics
Oral contraceptives
Experiment Findings Formulation and Evaluation of PCM Tablet.pdf
Factors affecting absorption of drugs
Nootropics (M.Pharm)
Soaps and syndetbars
Evaluation of antidepressants.pptx
Bio assay of d-tubocurarine
extravascular urin.pptx
A seminar on one & two compartment open model extra vascular administration
Expt 5 three point bioassay
IN-VITRO-IN VIVO CORRELATION (IVIVC).pptx
Screening of antidepressant
Microspheres - Methods for Preparation of Microspheres
Liposomes - Targeted drug delivery system
Bioavailability and bioequivalence
Absolute bioavailability & relative bioavailability
Controlled Release Oral Drug Delivery System
Methods for Measurement of bioavailability
EVOLUTION OF COSMECEUTICAL FROM COSMETIC
Analeptics
Ad

Viewers also liked (17)

PPT
Dose response relationship
PDF
4. pharmacokinetics and pharmacodynamics of gamithromycin
PPTX
Dose response
PDF
Perfect exposure & composition
PPT
Drug interactionppt
 
KEY
Lecture 1 6 2010-1
PPTX
An introduction to dermal exposure assessment
PDF
Pharmacokinetics: Lecture four
PPTX
A guide to exposure determination and the impact of artwork
ZIP
Exposure Basics: Learn to Correctly Expose Your Photographs
PPT
Lecture 1 & 2 Strategic Hrm 2006
PPTX
Bioavailability and Bioequivalence Studies
PPT
Health Effects Of Radiation Exposure
PPT
Radiographic exposure and image quality
PPTX
Environment protection act
PPT
Foreign exchange risk and exposure
PDF
Build Features, Not Apps
Dose response relationship
4. pharmacokinetics and pharmacodynamics of gamithromycin
Dose response
Perfect exposure & composition
Drug interactionppt
 
Lecture 1 6 2010-1
An introduction to dermal exposure assessment
Pharmacokinetics: Lecture four
A guide to exposure determination and the impact of artwork
Exposure Basics: Learn to Correctly Expose Your Photographs
Lecture 1 & 2 Strategic Hrm 2006
Bioavailability and Bioequivalence Studies
Health Effects Of Radiation Exposure
Radiographic exposure and image quality
Environment protection act
Foreign exchange risk and exposure
Build Features, Not Apps
Ad

Similar to Pharmacology introduction defination (20)

PDF
Pharmacokinetics / Biopharmaceutics - Bioavailability and Bioequivalence
PDF
Bioavailabilityand bioequivalence
DOCX
Bioavailability and bioequivalence of Drug Product.docx
PDF
BioavailabilityandBioequivalence.pdf
PPTX
2. BIOPHARMACEUTICS TERMINOLOGIES (2).pptx
PDF
Area Under the Curve (Pharmacokinetics)
PPT
Clinical pharmacology.Basics.
PPTX
Bioavailability and Bioequivalence -2- Types, Methods, Protocol.pptx
PPTX
toxicokinetics-1.pptx
PPTX
Biopharmaceutics
PPT
Experimental and clinical validation of classical and proproetary ayurvedic f...
PDF
Integrated Pharmacology 3rd Edition 3rd Clive Page Brian Hoffman
PPTX
Pharmacodynamics pharmacology of body drug reaction
PPTX
Introduction to pharmacokinetics and pharmacodynamics drug interaction
PPTX
Pharmacotherapeutics chapter 1 topic 1.pptx
PPTX
Bioavailability for General Phamacology
PPTX
Toxicology
PPT
Pharma 2016
PPTX
Introduction to Biopharmaceutics
Pharmacokinetics / Biopharmaceutics - Bioavailability and Bioequivalence
Bioavailabilityand bioequivalence
Bioavailability and bioequivalence of Drug Product.docx
BioavailabilityandBioequivalence.pdf
2. BIOPHARMACEUTICS TERMINOLOGIES (2).pptx
Area Under the Curve (Pharmacokinetics)
Clinical pharmacology.Basics.
Bioavailability and Bioequivalence -2- Types, Methods, Protocol.pptx
toxicokinetics-1.pptx
Biopharmaceutics
Experimental and clinical validation of classical and proproetary ayurvedic f...
Integrated Pharmacology 3rd Edition 3rd Clive Page Brian Hoffman
Pharmacodynamics pharmacology of body drug reaction
Introduction to pharmacokinetics and pharmacodynamics drug interaction
Pharmacotherapeutics chapter 1 topic 1.pptx
Bioavailability for General Phamacology
Toxicology
Pharma 2016
Introduction to Biopharmaceutics

More from Zulcaif Ahmad (20)

PPTX
Pharmacokinetics & Pharmacodynamic models, Tolerance, Hypersensitivity response
PPTX
Magnetically Modulated DDS
PPTX
Analgesic, Pain Ladder, Pain Assessment & Pain Treatment
PPTX
Solubility & Method for determination of solubility
PDF
Autonomic Nervous System drugs classification
DOCX
Drug (Anti-Psychotic drug) Induce Parkinsonism
DOCX
Alcohol Induce Liver Injury
DOCX
Drug induce hepatitis
PPTX
Pulmonary hypertension
PPTX
Macrolides and lincosamide
PPTX
Chopramphenicol
PPTX
Immunosuppressants
PPT
Anthelmintics Pharmacology
PPT
Quinolones
PPTX
Cancer chemotherapy
PPTX
Asthma
PPTX
Evaporation presentation
PPTX
Audit community pharmacy
PPTX
Quality Management
PPTX
Dispensing of controlled substances
Pharmacokinetics & Pharmacodynamic models, Tolerance, Hypersensitivity response
Magnetically Modulated DDS
Analgesic, Pain Ladder, Pain Assessment & Pain Treatment
Solubility & Method for determination of solubility
Autonomic Nervous System drugs classification
Drug (Anti-Psychotic drug) Induce Parkinsonism
Alcohol Induce Liver Injury
Drug induce hepatitis
Pulmonary hypertension
Macrolides and lincosamide
Chopramphenicol
Immunosuppressants
Anthelmintics Pharmacology
Quinolones
Cancer chemotherapy
Asthma
Evaporation presentation
Audit community pharmacy
Quality Management
Dispensing of controlled substances

Recently uploaded (20)

PPTX
Vesico ureteric reflux.. Introduction and clinical management
PPT
nephrology MRCP - Member of Royal College of Physicians ppt
PDF
Nursing manual for conscious sedation.pdf
PPTX
ANESTHETIC CONSIDERATION IN ALCOHOLIC ASSOCIATED LIVER DISEASE.pptx
PDF
AGE(Acute Gastroenteritis)pdf. Specific.
PPTX
4. Abdominal Trauma 2020.jiuiwhewh2udwepptx
PPTX
Post Op complications in general surgery
PPTX
Wheat allergies and Disease in gastroenterology
PDF
Forensic Psychology and Its Impact on the Legal System.pdf
PDF
B C German Homoeopathy Medicineby Dr Brij Mohan Prasad
PDF
Adverse drug reaction and classification
PPT
Rheumatology Member of Royal College of Physicians.ppt
PPT
neurology Member of Royal College of Physicians (MRCP).ppt
PPTX
NRP and care of Newborn.pptx- APPT presentation about neonatal resuscitation ...
PDF
OSCE Series ( Questions & Answers ) - Set 6.pdf
PDF
The_EHRA_Book_of_Interventional Electrophysiology.pdf
PPTX
Impression Materials in dental materials.pptx
PPTX
ROJoson PEP Talk: What / Who is a General Surgeon in the Philippines?
PPTX
SHOCK- lectures on types of shock ,and complications w
PDF
Lecture on Anesthesia for ENT surgery 2025pptx.pdf
Vesico ureteric reflux.. Introduction and clinical management
nephrology MRCP - Member of Royal College of Physicians ppt
Nursing manual for conscious sedation.pdf
ANESTHETIC CONSIDERATION IN ALCOHOLIC ASSOCIATED LIVER DISEASE.pptx
AGE(Acute Gastroenteritis)pdf. Specific.
4. Abdominal Trauma 2020.jiuiwhewh2udwepptx
Post Op complications in general surgery
Wheat allergies and Disease in gastroenterology
Forensic Psychology and Its Impact on the Legal System.pdf
B C German Homoeopathy Medicineby Dr Brij Mohan Prasad
Adverse drug reaction and classification
Rheumatology Member of Royal College of Physicians.ppt
neurology Member of Royal College of Physicians (MRCP).ppt
NRP and care of Newborn.pptx- APPT presentation about neonatal resuscitation ...
OSCE Series ( Questions & Answers ) - Set 6.pdf
The_EHRA_Book_of_Interventional Electrophysiology.pdf
Impression Materials in dental materials.pptx
ROJoson PEP Talk: What / Who is a General Surgeon in the Philippines?
SHOCK- lectures on types of shock ,and complications w
Lecture on Anesthesia for ENT surgery 2025pptx.pdf

Pharmacology introduction defination

  • 2. 2/12/2013 TOPIC 1) Bioavailability 2) Bioequivalence 3) Therapeutic index 4) Plasma half life 5) Dose response curve 6) Area under curve (AUC) 7) Volume of distribution 2
  • 3. 2/12/2013 PHARMACOKINETICS Pharmakon ( drug ) Kinetics ( motion )  Definition : The actions of the body on an administered drug ( dose concentration ). It involves drug absorption , distribution , metabolism and elimination . 3
  • 5. 2/12/2013 Pharmacokinetics conc. vs time Conc.(mg/L) 0.0 0 25 Time (h) 5
  • 6. 2/12/2013 1) BIOAVAILABILITY  In pharmacology, bioavailability is a measurement of the rate and extent to which a drug reaches the systemic circulation It is denoted by the letter f  Bioavailability is the ratio of the area calculated for oral route of administration to the intravenous route of administration.  In pharmacology, bioavailability (BA) is a subcategory of absorption and is the fraction of an administered dose of unchanged drug that reaches the systemic circulation, one of the principal pharmacokinetic properties of drugs. By definition, when a medication is administered intravenously, its bioavailability is 100%.  However, when a medication is administered via other routes (such as orally), its bioavailability generally decreases (due to incomplete absorption and first-pass metabolism) or may vary from patient to patient.  Bioavailability is one of the essential tools in pharmacokinetics, as bioavailability must be considered when calculating dosages for non- intravenous routes of administration. 6
  • 7. 2/12/2013 For a non-intravenous drug , it is less than 100% because of : 1) Absorption Parameters. 2)First-pass elimination.  Bioavailability is the drug proportion that actually reaches systemic circulation . 7
  • 9. 2/12/2013 2) BIOEQUIVALENCE  Relationship between 2 preparations of the same drug at same dose in same form with similar bioavailability. OR  The relationship between two preparations of the same drug in the same dosage form that have a similar bioavailability. 9
  • 10. 2/12/2013  Bioequivalence is a term in pharmacokinetics used to assess the expected in vivo biological equivalence of two proprietary preparations of a drug. If two products are said to be bioequivalent it means that they would be expected to be, for all intents and purposes, the same.  two pharmaceutical products are bioequivalent if they are pharmaceutically equivalent and their bioavailabilities (rate and extent of availability) after administration in the same molar dose are similar to such a degree that their effects, with respect to both efficacy and safety, can be expected to be essentially the same.  Pharmaceutical equivalence implies the same amount of the same active substance(s), in the same dosage form, for the same route of administration and meeting the same or comparable standards."[1] 10
  • 11. 2/12/2013 GRAPH SHOWING BIOEQUIVALENCE 90 80 mL) 70 Concentration (ng/ 60 Test/Generic 50 Reference/Brand 40 30 20 10 0 0 5 10 15 20 25 30 Time (hours) 11
  • 12. 2/12/2013 3) THERAPEUTIC INDEX  The difference between the minimum therapeutic and minimum toxic concentrations of a drug.  Therapeutic index represents the safety of a drug.  Drugs having low therapeutic index include: Anticonvulsants, lithium, anticoagulants, corticosteroids and cardio active drugs. 12
  • 13. 2/12/2013  therapeutic index (also known as therapeutic ratio) is a comparison of the amount of a therapeutic agent that causes the therapeutic effect to the amount that causes death (in animal studies) or toxicity (in human studies).  the ratio between the dosage of a drug that causes a lethal effect and the dosage that causes therapeutic effect.  Medical Dictionary : The ratio between the toxic dose and the therapeutic dose of a drug, used as a measure of the relative safety of the drug for a particular treatment. 13
  • 14. 2/12/2013 4) PLASMA HALF LIFE  The duration of action of a drug is known as its half life.  This is the period of time required for the concentration or amount of drug in the body to be reduced by one-half.  Drug can be eliminated from the body, or it can be translocated to another body fluid compartment such as the intracellular fluid or it can be destroyed in the blood after it is reduced to half life.  The removal of a drug from the plasma is known as clearance and the distribution of the drug in the various body tissues is known as the volume of distribution. Both of these pharmacokinetic parameters are important in determining the half life of a drug.  Here is the symbol to represent the half-life: t½ 14
  • 15. 2/12/2013  The biological half-life or elimination half- life of a substance is the time it takes for a substance (for example a metabolite, drug, signaling molecule, radioactive nuclide, or other substance) to lose half of its pharmacologic, physiologic, or radiologic activity , as per the MeSH definition.  Biological half-life is an important pharmacokinetic parameter . 15
  • 16. 2/12/2013 16
  • 17. 2/12/2013 5) DOSE-RESPONSE CURVE  A dose–response curve is a simple X–Y graph relating the magnitude of a stressor ( e.g. amount of drug ) to the response of receptor.  The measured dose (usually in milligrams, micrograms, or grams per kilogram of body- weight for oral exposures or milligrams per cubic meter of ambient air for inhalation exposures) is generally plotted on the X axis and the response is plotted on the Y axis.  The dose–response relationship , describes the change in effect on an organism caused by differing levels of exposure (or doses) to a stressor (usually a chemical) after a certain exposure time.[1] This may apply to individuals (e.g.: a small amount has no significant effect, a large amount is fatal), or to populations (e.g.: how many people or organisms are affected at different levels of exposure).  Studying dose response, and developing dose response models, is central to determining "safe" and "hazardous" levels and dosages for drugs, potential pollutants, and other substances to which humans or other organisms are exposed. These conclusions are often the basis for public policy.  Dose–response relationships generally depend on the exposure time and exposure route (e.g., inhalation, dietary intake); quantifying the response after a different exposure time or for a different route leads to a different relationship and possibly different conclusions on the effects of the stressor under consideration. 17
  • 18. 2/12/2013 6) AREA UNDER CURVE (AUC)  The area under the plot of plasma concentration of drug (not logarithm of the concentration) against time after drug administration  The area under the plasma (serum, or blood) concentration versus time curve (AUC) has a number of important uses in pharmacokinetics.  The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs (ClT). 18
  • 19. 2/12/2013 19
  • 20. 2/12/2013  AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much - how long a drug stays in a body.  The AUC measured after administration of a drug product is an important parameter in the comparison of drug products. These bioequivalence or bioavailability studies can be analyzed by comparing AUC values.  Drug AUC values can be used to determine other pharmacokinetic parameters, such as clearance or bioavailability, F. Similar techniques can be used to calculate area under the first moment curve (AUMC) 20
  • 21. 2/12/2013 7) VOLUME OF DISTRIBUTION  Volume of distribution is the measure of the apparent space in the body available to contain the drug.  Volume of distribution relates the amount of drug in the body to the concentration of drug in blood or plasma .  Formula for volume of distribution is , total amount of drug in the body divided by drug blood plasma concentration.  It is not a real but a theoretical volume.  if VD is greater, it shows that the drug is more diluted than it should be (in the blood plasma), meaning more of it is distributed in tissue (i.e. not in plasma).  It is defined as the distribution of a medication between plasma and the rest of the body after oral or parenteral dosing. 21
  • 22. 2/12/2013  Volume of distribution may be increased by renal failure (due to fluid retention) and liver failure (due to altered body fluid).  Conversely it may be decreased in dehydration. 22
  • 23. 2/12/2013 23
  • 24. 2/12/2013 REFERENCE  http://bipolar.about.com/od/medications/g/gl_bio availabil.htm  http://faculty.ksu.edu.sa/hisham/Documents/Stu dents/a_PHCL/pkin08.pdf  http://www.wisegeek.com/what-is- bioequivalence.htm#did-you-know  Stedman's medical dictionary .  Medical-dictionary.thefreemedicaldictionary.com  www.freedictionry.com 24

Editor's Notes

  • #4: which can, in many respects, be envisioned more accurately as the actions of the body on an administered drug. It includes studies of the mechanisms of drug absorption, distribution, metabolism, and excretion; onset of action; duration of effect; biotransformation; and effects and routes of excretion of the metabolites of the drug. Pharmacokinetics determine how rapidly and for how long the drug will apear at the target organ.
  • #7: . the degree to which a drug or other substance becomes available to the target tissue after administration. A measure of the amount of drug that is actually absorbed from a given dose. the degree to which a drug or other substance becomes available to the target tissue after administration. Clinical pharmacology The degree to which a drug is available to a target tissue after administration which, for oral drugs, reflects the rate and extent of GI tract absorption; BA is the in vivo presence of a substance in a form that allows it to be metabolized, serve as a substrate, bind a specific molecule, or participate in biochemical reactions. For dietary supplements, herbs and other nutrients in which the route of administration is nearly always oral, bioavailability generally designates simply the quantity or fraction of the ingested dose that is absorbed.[2]Bioavailability is defined slightly differently for drugs as opposed to dietary supplements primarily due to the method of administration and Food and Drug Administration regulations.Bioaccessibility is a concept related to bioavailability in the context of biodegradation and environmental pollution. A molecule (often a persistent organic pollutant) is said to be bioavailable when "[it] is available to cross an organism’s cellular membrane from the environment, if the organism has access to the chemical." 
  • #8: Absorption parameters : gastrointestinal track.
  • #11: BioequivalenceIn determining bioequivalence, for example, between two products such as a commercially-available Brand product and a potential to-be-marketed Generic product, pharmacokinetic studies are conducted whereby each of the preparations are administered in a cross-over study to volunteer subjects, generally healthy individuals but occasionally in patients. Serum/plasma samples are obtained at regular intervals and assayed for parent drug (or occasionally metabolite) concentration. Occasionally, blood concentration levels are neither feasible or possible to compare the two products (e.g. inhaled corticosteroids), then pharmacodynamic endpoints rather than pharmacokinetic endpoints (see below) are used for comparison. For a pharmacokinetic comparison, the plasma concentration data are used to assess key pharmacokinetic parameters such as area under the curve (AUC), peak concentration (Cmax), time to peak concentration (Tmax), and absorption lag time (tlag). Testing should be conducted at several different doses, especially when the drug displays non-linear pharmacokinetics.In addition to data from bioequivalence studies, other data may need to be submitted to meet regulatory requirements for bioequivalence. Such evidence may include:1. analytical method validation2. In vitro-in vivo correlation studies(IVIVC)
  • #12: Establish that a new formulation has therapeutic equivalence in the rate and extent of absorption to the reference drug product.Generic drug : a medication sold under its generic name ; usully legal only after the patent has expired or if no patent was issued for the substance . Generic drugs are usually less expensive than proprietry medication .
  • #13: Anti-convulsants : a drug that relieves or prevent convulsions, A type of drug given to prevent seizures ,some patients with migrines can be treated effectively with an anti-convulsants. ( conulsions : an involuntry contraction or series of contraction of the voluntry muscles ).Anti-coagulants : substance that prevents coagulation of blood .Corticosteroids : Cardio-active drug :
  • #14: the ratio between the dosage of a drug that causes a lethal effect and the dosage that causes atherapeutic effect.Medical Dictionarytherapeutic index n.  The ratio between the toxic dose and the therapeutic dose of a drug, used as a measure of the relativesafety of the drug for a particular treatment.Quantitatively, it is the ratio given by the lethal or toxic dose divided by the therapeutic dose.In animal studies, the therapeutic index is the lethal dose of a drug for 50% of the population (LD50) divided by the minimum effective dose for 50% of the population (ED50).Lethality is not determined in human clinical trials; instead, the dose that produces a toxicity in 50% of the population (TD50) is used to calculate the therapeutic index.While the lethal dose is important to determine in animal studies, there are usually severe toxicities that occur at sublethal doses in humans, and these toxicities often limit the maximum dose of a drug. A higher therapeutic index is preferable to a lower one: a patient would have to take a much higher dose of such a drug to reach the lethal/toxic threshold than the dose taken to elicit the therapeutic effect.
  • #15: Examples of biological half-lives[edit]WaterThe biological half-life of water in a human is about 7 to 14 days. It can be altered by behavior. Drinking large amounts of alcohol will reduce the biological half-life of water in the body.[3][4] This has been used to decontaminate humans who are internally contaminated with tritiated water (tritium). Drinking the same amount of water would have a similar effect, but many would find it difficult to drink a large volume of water. The basis of this decontamination method (used at Harwell) is to increase the rate at which the water in the body is replaced with new water.[edit]AlcoholThe removal of ethanol (drinking alcohol) through oxidation by alcohol dehydrogenase in the liver from the human body is limited. Hence the removal of a large concentration of alcohol from blood may follow zero-order kinetics. Also the rate-limiting steps for one substance may be in common with other substances. For instance, the blood alcohol concentration can be used to modify the biochemistry of methanol and ethylene glycol. In this way the oxidation of methanol to the toxic formaldehyde and formic acid in the (human body) can be prevented by giving an appropriate amount of ethanol to a person who has ingested methanol. Note that methanol is very toxic and causes blindness and death. A person who has ingested ethylene glycol can be treated in the same way. complex kineticsMetalsThe biological half-life of caesium in humans is between one and four months. This can be shortened by feeding the person prussian blue. The prussian blue in the digestive system acts as a solid ion exchanger which absorbs the caesium while releasing potassium ions.For some substances, it is important to think of the human or animal body as being made up of several parts, each with their own affinity for the substance, and each part with a different biological half-life (physiologically-based pharmacokinetic modelling). Attempts to remove a substance from the whole organism may have the effect of increasing the burden present in one part of the organism. For instance, if a person who is contaminated with lead is given EDTA in a chelation therapy, then while the rate at which lead is lost from the body will be increased, the lead within the body tends to relocate into the brain where it can do the most harm.[citation needed]Polonium in the body has a biological half-life of about 30 to 50 days.Caesium in the body has a biological half-life of about one to four months.Mercury (as methylmercury) in the body has a half-life of about 65 days.Lead in bone has a biological half-life of about ten years.Cadmium in bone has a biological half-life of about 30 years.Plutonium in bone has a biological half-life of about 100 years.Plutonium in the liver has a biological half-life of about 40 years.
  • #16: MeSH definition : an abbreviations derived from MEDICAL SUBJECT HEADINGS , the list of medical terms used by NATIONAL LIBRARY OF MEDICINE ( NLM ) for its computerized system of storage and retrivel of published medical reports , this system is also used for indexing medical reference published in the monthly and annual volumes of index medicus …16000 terms .
  • #19: AUC (area-under-the-curve): This is the overall amount of drug in the bloodstream after a dose. AUC studies are often used when researchers are looking for drug-drug or drug-food interactions. The way to get an AUC involves collecting many blood samples (usually every one or two hours) right after a person takes a dose up until the next dose is due. In each blood sample, the concentration of the drug is measured with a machine (discussed later). Then all the drug concentrations are put onto a graph based on the time after the dose that they were collected. A curve is made by connecting the points on the graph. The AUC for that drug is then calculated as the area under this drug concentration curve. An AUC study contains a lot of information about PK. It is probably the best way to understand how people handle a drug (PK).Cmax (maximum concentration): This is the highest concentration of drug in the blood that is measured after a dose. Cmaxusually happens within a few hours after the dose is taken. The time that Cmaxhappens is referred to as Tmax. For some antiretroviral drugs, a high Cmax is thought to increase the risk of side effects from the drug.Cmin or trough (pronounced "troff")(minimum concentration): This is the lowest concentration of the drug in the blood that is measured after a dose. It happens right before a patient takes the next usual dose. It is not known for certain, but many people in the HIV community believe that keeping the trough concentration (Cmin) above a certain level is especially important for anti-HIV activity.
  • #20: Cmax , The maximum drug concentration. The maximum concentration of drug in the plasma is a function of both the rate and extent of absorption. Cmax will increase with an increase in the dose, as well as with an increase in the absorption rate. 3. Tmax , The time at which the Cmax occurs. The Tmax reflects the rate of drug absorption, and decreases as the absorption rate increases.
  • #21: Area under first moment curve (AUMC) : plasma drug concentration x time after dosing versus time after drug administration.Mean resident times (MRT) : it is used for linear and non-linear systems.
  • #22: Lipophilic drug :Hydrophilic drug :